{"id":"NCT03143153","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","officialTitle":"A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-29","primaryCompletion":"2021-01-18","completion":"2025-01-13","firstPosted":"2017-05-08","resultsPosted":"2022-03-02","lastUpdate":"2025-02-25"},"enrollment":970,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Various Advanced Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558 (Nivolumab)","Opdivo (Nivolumab)"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["BMS-734016 (Ipilimumab)","Yervoy (Ipilimumab)"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Fluorouracil","otherNames":[]}],"arms":[{"label":"Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"label":"Nivolumab + Cisplatin + Fluorouacil","type":"EXPERIMENTAL"},{"label":"Cisplatin + Fluorouracil","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin","primaryOutcome":{"measure":"Overall Survival (OS) in Participants With Tumor Cell PD-L1","timeFrame":"From the date of randomization to up to the date of death (up to approximately 20 months)","effectByArm":[{"arm":"Arm A: Nivolumab + Ipilimumab","deltaMin":13.7,"sd":null},{"arm":"Arm B: Nivolumab + Chemotherapy","deltaMin":15.44,"sd":null},{"arm":"Arm C: Chemotherapy","deltaMin":9.07,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0010"},{"comp":"OG000 vs OG002","p":"0.0010"},{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":190,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","France","Hong Kong","Italy","Japan","Mexico","Peru","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["37139963","36401133","35108470"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":237,"n":322},"commonTop":["Nausea","Decreased appetite","Constipation","Anaemia","Diarrhoea"]}}